Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort : Strong correlation with BCL2 translocation. / Schejbel, Lone; Breinholt, Marie Fredslund; Gang, Anne Ortved; Nielsen, Torsten Holm; Pedersen, Lars Møller; Høgdall, Estrid; Nørgaard, Peter.

In: eJHaem, Vol. 3, No. 3, 2022, p. 936-939.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Schejbel, L, Breinholt, MF, Gang, AO, Nielsen, TH, Pedersen, LM, Høgdall, E & Nørgaard, P 2022, 'Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation', eJHaem, vol. 3, no. 3, pp. 936-939. https://doi.org/10.1002/jha2.489

APA

Schejbel, L., Breinholt, M. F., Gang, A. O., Nielsen, T. H., Pedersen, L. M., Høgdall, E., & Nørgaard, P. (2022). Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation. eJHaem, 3(3), 936-939. https://doi.org/10.1002/jha2.489

Vancouver

Schejbel L, Breinholt MF, Gang AO, Nielsen TH, Pedersen LM, Høgdall E et al. Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation. eJHaem. 2022;3(3):936-939. https://doi.org/10.1002/jha2.489

Author

Schejbel, Lone ; Breinholt, Marie Fredslund ; Gang, Anne Ortved ; Nielsen, Torsten Holm ; Pedersen, Lars Møller ; Høgdall, Estrid ; Nørgaard, Peter. / Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort : Strong correlation with BCL2 translocation. In: eJHaem. 2022 ; Vol. 3, No. 3. pp. 936-939.

Bibtex

@article{12f95d40bb1947dca7e59e755bf76cc9,

title = "Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation",

abstract = "Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment na{\"i}ve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.",

author = "Lone Schejbel and Breinholt, {Marie Fredslund} and Gang, {Anne Ortved} and Nielsen, {Torsten Holm} and Pedersen, {Lars M{\o}ller} and Estrid H{\o}gdall and Peter N{\o}rgaard",

note = "{\textcopyright} 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

doi = "10.1002/jha2.489",

language = "English",

volume = "3",

pages = "936--939",

journal = "eJHaem",

issn = "2688-6146",

publisher = "Wiley",

number = "3",

}

RIS

TY - JOUR

T1 - Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort

T2 - Strong correlation with BCL2 translocation

AU - Schejbel, Lone

AU - Breinholt, Marie Fredslund

AU - Gang, Anne Ortved

AU - Nielsen, Torsten Holm

AU - Pedersen, Lars Møller

AU - Høgdall, Estrid

AU - Nørgaard, Peter

PY - 2022

Y1 - 2022

N2 - Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.

AB - Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.

U2 - 10.1002/jha2.489

DO - 10.1002/jha2.489

M3 - Journal article

C2 - 36051027

VL - 3

SP - 936

EP - 939

JO - eJHaem

JF - eJHaem

SN - 2688-6146

IS - 3

ER -

ID: 345683026